

**BUY** **IndusInd Bank**

Your success is our success

**Focused on delivering sustainable growth, profitability**BFSI - Banks ▶ Result Update ▶ **October 19, 2023****TARGET PRICE (Rs) : 1,825**

**IndusInd Bank (IIB) reported largely in-line PAT at Rs22bn (up 22% YoY)/RoA at 1.9%, led by healthy credit growth/NII and lower LLP. Amid decelerating margins across banks, IIB retained NIM at ~4.3% in 2Q on the back of strong growth and better portfolio mix. Going ahead, IIB will continue focusing on retailization of its balance sheet, coupled with increasing share of secured mortgages, which should provide sustainability in growth, margins and asset quality in the long run.**

**We believe the stock performance is largely tracking the bank's strong credit growth, stable margins amid contraction among peers, and healthy asset-quality behavior with less exposure to unsecured loans (ex-MFI). Additionally, IIB is trading at reasonable valuations of 1.7x its FY25E ABV which, coupled with its robust return profile (RoA@1.9%/16-18% RoE over FY24-26E) and CET 1 at 16.3%, grants us confidence on the stock performance ahead. Promoters too are keen on increasing their stake in the bank and may look at capital infusion. We value the stock at 2x Sep-25E ABV and revise our TP to Rs1,825/sh (from Rs1,800). We retain BUY on IIB.**

**IndusInd Bank: Financial Snapshot (Standalone)**

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	46,111	73,897	92,777	1,11,875	1,40,471
Loan growth (%)	12.4	21.3	20.1	23.2	23.0
NII growth (%)	10.9	17.3	17.6	19.5	21.7
NIM (%)	4.2	4.4	4.4	4.4	4.4
PPOP growth (%)	9.5	11.7	13.2	20.7	24.9
Adj. EPS (Rs)	59.5	95.2	119.4	144.0	180.8
Adj. EPS growth (%)	62.3	60.0	25.4	20.6	25.6
Adj. BV (INR)	584.8	646.6	716.9	826.7	965.8
Adj. BVPS growth (%)	8.6	10.6	10.9	15.3	16.8
RoA (%)	1.2	1.7	1.9	1.9	1.9
RoE (%)	10.2	14.5	15.9	16.7	18.1
P/E (x)	23.9	14.9	11.9	9.9	7.9
P/ABV (x)	2.4	2.2	2.0	1.7	1.5

Source: Company, Emkay Research

**Strong growth, stable margins**

Bank continues to clock strong credit growth at 21% YoY/5% QoQ, primarily led by healthy growth in the retail, SME/BB and corporate segments. However, deposits growth was relatively moderate at 14% YoY/4% QoQ, leading to LDR expansion. Retail deposits and deposits from small business customers continued to increase, coming in at 21% YoY/4% QoQ. CASA ratio slipped slightly to 39.3%. Nonetheless, the bank continued to report stable margins at ~4.3% due to strong credit growth, contained cost and better portfolio mix. Management retains its broad growth guidance range of 18-23% for FY24 as well as its focus on retailization of assets/liability, which should help sustain healthy margin/core-profitability.

**Asset quality holds up well**

Fresh slippages remain elevated at Rs14.7bn/2.3% of loans which, along with healthy recoveries/write-offs, led to stable GNPA ratio of 1.9%. IIB has further utilized the contingency provision in 2Q, with the outstanding now at Rs15.2bn/0.5% of loans. Notably, the bank has relatively lower exposure to unsecured loans and should thus be relatively less vulnerable to RBI intervention, if any, on its undeterred growth in the segment.

**We retain BUY, with revised TP of Rs1,825/share**


We believe the stock performance is largely tracking the bank's strong credit growth, stable margins amid contraction among peers, and healthy asset-quality behavior with less exposure to unsecured loans (ex-MFI). Additionally, the bank is trading at reasonable valuations of 1.7x its FY25E ABV which, coupled with its healthy return profile (RoA@1.9%/16-18% RoE over FY24-26E) and CET 1 at 16.4%, makes us constructive about the stock performance ahead. Promoters too are keen on increasing their stake in the bank, and may look at capital infusion. We retain BUY on IIB, with revised TP of Rs1,825/share, valuing the bank at 2x Sep-25E ABV. **Key Risks:** Slower-than-expected credit growth/asset-quality deterioration, on weak macros.

Target Price – 12M	Sep-24
<b>Change in TP (%)</b>	<b>1.4</b>
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	28.5
CMP (18-Oct-23) (Rs)	1,420.4

Stock Data	Ticker
52-week High (Rs)	1,476
52-week Low (Rs)	990
Shares outstanding (mn)	777.1
Market-cap (Rs bn)	1,104
Market-cap (USD mn)	13,255
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	3,915.6
ADTV-3M (USD mn)	47.0
Free float (%)	84.0
Nifty-50	19,671
INR/USD	83.3
<b>Shareholding, Jun-23</b>	
Promoters (%)	15.1
FPIs/MFs (%)	38.6/24.8

**Price Performance**

(%)	1M	3M	12M
Absolute	(2.5)	2.2	16.1
Rel. to Nifty	(0.2)	2.6	3.2

**1-Year share price trend (Rs)****Anand Dama**

anand.dama@emkayglobal.com  
+91 22 6624 2480

**Kunaal N**


kunaal.n@emkayglobal.com  
+91 22 6612 1275

**Marazbaan Dastur**

marazbaan.dastur@emkayglobal.com  
+91 22 6612 1281


# Story in Charts

**Exhibit 1: Healthy credit growth led by strong traction in the retail book; moderate deposits growth**




Source: Company, Emkay Research

**Exhibit 2: Margins remain fairly stable owing to retailization strategy, in spite of CoD inching up by 23bps**




Source: Company, Emkay Research

**Exhibit 3: Fresh slippages remain elevated...**




Source: Company, Emkay Research

**Exhibit 4: ...but better recoveries/growth lead to moderation in GNPA ratio**




Source: Company, Emkay Research

**Exhibit 5: Stress increased in the Cards and MFI portfolios, while VF remains moderate**




Source: Company, Emkay Research

**Exhibit 6: Return ratios expected to rise on the back of strong credit growth and lower LLP**



Source: Company, Emkay Research

**Exhibit 7: The stock trades at 2x its one-year forward ABV**



Source: Bloomberg, Emkay Research

**Exhibit 8: Actuals vs. Estimates (Q2FY24)**

(Rs mn)	Actuals	Estimates		Variation		Comments
		Emkay	Consensus	Emkay	Consensus	
Net income	73,586	73,878	72,899	0%	1%	Stable margins led to in-line net income
PPOP	39,087	40,349	40,251	-3%	-3%	Higher staff expenses led to a shortfall in PPOP
PAT	22,012	22,153	22,301	-1%	-1%	Shortfall in PPOP and higher provisions led to a shortfall in PAT

Source: Company, Emkay Research

**Exhibit 9: Quarterly Summary**

(Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)	FY23A	FY24E	YoY (%)
Interest Earned	87,080	94,574	1,00,207	1,07,297	1,12,478	29	5	3,63,679	4,61,726	27
Interest Exp	44,060	49,621	53,513	58,625	61,711	40	5	1,87,758	2,54,880	36
Net Interest Income	43,021	44,954	46,695	48,671	50,767	18	4	1,75,921	2,06,846	18
Global NIMs (reported)	4.24	4.27	4.28	4.29	4.29	5bps	0bps	4.37	4.42	5bps
Non-interest Income	20,112	20,765	21,536	22,098	22,819	13	3	81,664	93,877	15
Operating Expenses	27,689	28,854	30,656	32,455	34,499	25	6	1,14,120	1,38,309	21
Pre Provisioning Profit	35,444	36,864	37,575	38,315	39,087	10	2	1,43,465	1,62,414	13
Provision & Contingencies	11,411	10,647	10,301	9,916	9,738	-15	-2	44,868	38,381	-14
PBT	24,033	26,217	27,275	28,399	29,349	22	3	98,596	1,24,033	26
Income Tax Expense	5,981	6,582	6,841	7,155	7,329	23	2	24,699	31,256	27
Net Profit/(Loss)	18,052	19,635	20,434	21,244	22,021	22	4	73,897	92,777	26
Gross NPA (%)	2.11	2.06	1.98	1.94	1.93	-18bps	-2bps	1.98	1.82	-16bps
Net NPA (%)	0.61	0.62	0.59	0.58	0.57	-3bps	0bps	0.59	0.55	-4bps
Deposits (Rs bn)	3,155	3,253	3,361	3,470	3,595	14	4	3,364	4,001	19
Net Advances (Rs bn)	2,601	2,728	2,899	3,013	3,155	21	5	2,899	3,483	20

Source: Company, Emkay Research

**Exhibit 10: Revision in Estimates**

Y/E Mar (Rs mn)	FY24E			FY25E			FY26E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	3,01,209	3,00,723	-0.2%	3,53,964	3,58,606	1.3%	4,32,767	4,35,489	0.6%
PPOP	1,65,250	1,62,414	-1.7%	1,94,052	1,95,960	1.0%	2,44,446	2,44,692	0.1%
PAT	90,886	92,777	2.1%	1,11,195	1,11,875	0.6%	1,39,913	1,40,471	0.4%
EPS (Rs)	117.1	119.4	1.9%	143.3	144.0	0.5%	180.3	180.8	0.3%
BV (Rs)	755.9	733.9	-2.9%	870.2	845.2	-2.9%	1017.1	988.0	-2.9%

Source: Company, Emkay Research

**Exhibit 11: Key assumptions**

	FY23A	FY24E	FY25E	FY26E
Loan Growth (%)	21.3	20.1	23.2	23.0
Deposit Growth (%)	14.6	18.9	23.1	22.5
NIM (%)	4.4	4.4	4.4	4.4
GNPA (%)	2.0	1.8	1.6	1.6
Credit Cost (%)	1.6	1.2	1.2	1.2

Source: Emkay Research

## Exhibit 12: Key Ratios and trends

	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Loans (Rs bn)	2,208	2,286	2,391	2,480	2,601	2,728	2,899	3,013	3,155
growth YoY (%)	9.7	10.4	12.4	17.7	17.8	19.3	21.3	21.5	21.3
growth QoQ (%)	4.8	3.5	4.6	3.7	4.9	4.9	6.3	3.9	4.7
<b>Composition (%)</b>									
- Large Corporate	22.8	23.5	25.2	25.1	26.4	26.1	25.6	25.6	25.1
- SME/Business Banking	27.0	27.6	25.6	25.9	25.2	25.2	25.4	25.6	25.1
- Retail	50.1	48.9	49.2	48.9	48.4	48.7	49.0	48.8	49.7
<b>Liability Profile</b>									
Deposits (Rs bn)	2,753	2,845	2,933	3,027	3,155	3,253	3,361	3,470	3,595
growth YoY (%)	20.8	19.0	14.6	13.3	14.6	14.3	14.6	14.6	13.9
growth QoQ (%)	3.0	3.3	3.1	3.2	4.2	3.1	3.3	3.3	3.6
CASA (%)	42.1	42.1	42.7	43.1	42.3	41.9	40.1	39.9	39.3
CA (%)	11.8	11.7	12.4	11.6	14.0	15.4	15.1	14.2	13.9
SA (%)	30.3	30.4	30.3	31.5	28.3	26.6	25.0	25.7	25.5
Branches (no. of)	2,015	2,103	2,265	2,286	2,320	2,384	2,606	2,606	2,631
Yield on Advances (%)	11.66	11.36	11.29	11.39	11.51	11.75	12.02	12.24	12.30
Cost of Deposits (%)	4.85	4.66	4.60	4.79	5.10	5.47	5.81	6.12	6.35
NIM (%)	4.07	4.10	4.20	4.21	4.24	4.27	4.28	4.29	4.29
<b>Asset Quality</b>									
GNPA (%)	2.8	2.5	2.3	2.4	2.1	2.1	2.0	2.0	2.0
NNPA (%)	0.8	0.7	0.6	0.7	0.6	0.6	0.6	0.6	0.6
PCR (%)	71.6	71.7	72.3	72.0	71.5	70.6	70.6	70.6	70.6
Slippages (Rs mn)	26,580	25,980	20,880	22,500	15,720	14,670	16,030	13,760	14,650
Corporate (Rs mn)	2,520	560	3,460	6,020	1,790	1,190	2,640	430	2,140
Consumer (Rs mn)	24,060	25,420	17,420	16,480	13,930	13,480	13,390	13,330	12,510
Slippages (%)	5.3	5.0	3.9	4.3	2.8	2.6	2.7	2.2	2.3
CAR (%)	17.4	18.1	18.4	18.1	18.0	18.0	17.9	18.4	18.2
Tier I (%)	16.7	16.4	16.8	16.6	16.4	16.5	16.4	16.9	16.9
<b>ROE Decomposition (%)</b>									
NII	3.9	3.9	4.0	4.1	4.1	4.1	4.1	4.2	4.3
Other Income	1.6	1.6	1.7	1.8	1.8	1.8	1.8	1.8	1.8
Opex	2.4	2.4	2.5	2.6	2.6	2.7	2.7	2.8	2.9
PPOP	3.4	3.4	3.4	3.4	3.4	3.4	3.3	3.3	3.3
Provisioning Cost	1.8	1.7	1.5	1.2	1.1	1.0	0.9	0.9	0.8
PBT	1.6	1.7	1.9	2.1	2.3	2.4	2.4	2.5	2.5
Tax	0.4	0.4	0.5	0.5	0.6	0.6	0.6	0.6	0.6
ROA	1.2	1.3	1.4	1.6	1.7	1.8	1.8	1.8	1.9
Leverage (x)	8.4	8.4	8.4	8.3	8.3	8.4	8.4	8.2	8.2
ROE	10.2	10.8	11.8	13.4	14.4	15.1	15.2	15.2	15.2

Source: Company, Emkay Research

## IndusInd Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	3,08,224	3,63,679	4,61,726	5,43,644	6,44,707
Interest Expense	1,58,216	1,87,758	2,54,880	2,96,380	3,43,812
<b>Net interest income</b>	<b>1,50,008</b>	<b>1,75,921</b>	<b>2,06,846</b>	<b>2,47,264</b>	<b>3,00,895</b>
NII growth (%)	10.9	17.3	17.6	19.5	21.7
Other income	73,970	81,664	93,877	1,11,342	1,34,594
<b>Total Income</b>	<b>2,23,979</b>	<b>2,57,585</b>	<b>3,00,723</b>	<b>3,58,606</b>	<b>4,35,489</b>
Operating expenses	95,593	1,14,120	1,38,309	1,62,646	1,90,796
<b>PPOP</b>	<b>1,28,386</b>	<b>1,43,465</b>	<b>1,62,414</b>	<b>1,95,960</b>	<b>2,44,692</b>
PPOP growth (%)	9.5	11.7	13.2	20.7	24.9
<b>Core PPOP</b>	<b>1,22,454</b>	<b>1,43,631</b>	<b>1,57,965</b>	<b>1,89,954</b>	<b>2,39,291</b>
Provisions & contingencies	66,650	44,868	38,381	46,395	56,897
<b>PBT</b>	<b>61,736</b>	<b>98,596</b>	<b>1,24,033</b>	<b>1,49,566</b>	<b>1,87,796</b>
Extraordinary items	0	0	0	0	0
Tax expense	15,625	24,699	31,256	37,691	47,325
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>46,111</b>	<b>73,897</b>	<b>92,777</b>	<b>1,11,875</b>	<b>1,40,471</b>
PAT growth (%)	62.6	60.3	25.5	20.6	25.6
<b>Adjusted PAT</b>	<b>46,111</b>	<b>73,897</b>	<b>92,777</b>	<b>1,11,875</b>	<b>1,40,471</b>
<b>Diluted EPS (Rs)</b>	<b>62.0</b>	<b>95.2</b>	<b>119.3</b>	<b>143.8</b>	<b>180.6</b>
Diluted EPS growth (%)	55.1	53.5	25.4	20.6	25.6
<b>DPS (Rs)</b>	<b>8.5</b>	<b>14.0</b>	<b>18.0</b>	<b>22.5</b>	<b>25.0</b>
<b>Dividend payout (%)</b>	<b>14.3</b>	<b>14.7</b>	<b>15.1</b>	<b>15.6</b>	<b>13.8</b>
Effective tax rate (%)	25.3	25.1	25.2	25.2	25.2
Net interest margins (%)	4.2	4.4	4.4	4.4	4.4
Cost-income ratio (%)	42.7	44.3	46.0	45.4	43.8
Shares outstanding (mn)	774.7	775.9	777.1	777.1	777.1

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
<b>Asset quality</b>					
Gross NPLs	55,171.5	58,262.6	64,260.9	70,163.2	83,775.5
Net NPLs	15,298.3	17,149.5	19,278.3	21,049.0	25,132.6
GNPA ratio (%)	2.3	2.0	1.8	1.6	1.6
NNPA ratio (%)	0.6	0.6	0.6	0.5	0.5
Provision coverage (%)	72.3	70.6	70.0	70.0	70.0
Gross slippages	1,01,028.7	68,920.0	59,983.0	73,779.1	90,748.3
Gross slippage ratio (%)	4.2	2.3	1.7	1.7	1.7
LLP ratio (%)	2.7	1.6	1.2	1.2	1.2
NNPA to networth (%)	3.0	2.9	2.9	2.7	2.8
<b>Capital adequacy</b>					
Total CAR (%)	18.4	17.9	17.6	16.8	16.0
Tier-1 (%)	16.8	16.4	16.0	15.3	14.7
CET-1 (%)	16.8	16.4	16.0	15.3	14.7
RWA-to-Total Assets (%)	73.4	78.4	79.5	79.5	79.6
<b>Miscellaneous</b>					
Total income growth (%)	7.5	16.5	24.8	17.9	19.0
Opex growth (%)	14.3	19.4	21.2	17.6	17.3
Core PPOP growth (%)	19.6	17.3	10.0	20.3	26.0
PPOP margin (%)	3.4	3.3	3.2	3.3	3.4
PAT/PPOP (%)	35.9	51.5	57.1	57.1	57.4
LLP-to-Core PPOP (%)	54.4	31.2	24.3	24.4	23.8
Yield on advances (%)	11.2	11.4	12.1	11.9	11.6
Cost of funds (%)	4.9	5.2	6.1	5.9	5.6

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	7,747	7,759	7,771	7,771	7,771
Reserves & surplus	4,69,065	5,38,458	6,21,201	7,16,204	8,36,373
<b>Net worth</b>	<b>4,76,812</b>	<b>5,46,217</b>	<b>6,28,971</b>	<b>7,23,975</b>	<b>8,44,143</b>
Deposits	29,36,813	33,64,381	40,01,196	49,24,123	60,30,351
Borrowings	4,73,232	4,90,112	5,35,033	5,84,146	6,63,234
<b>Interest bearing liab.</b>	<b>34,10,046</b>	<b>38,54,494</b>	<b>45,36,229</b>	<b>55,08,269</b>	<b>66,93,585</b>
<b>Other liabilities &amp; prov.</b>	<b>1,32,889</b>	<b>1,77,773</b>	<b>2,64,059</b>	<b>3,08,165</b>	<b>4,09,292</b>
<b>Total liabilities &amp; equity</b>	<b>40,19,746</b>	<b>45,78,484</b>	<b>54,29,259</b>	<b>65,40,409</b>	<b>79,47,020</b>
Net advances	23,90,515	28,99,237	34,83,431	42,90,835	52,79,494
Investments	7,09,708	8,31,162	9,72,376	11,29,142	13,77,369
Cash, other balances	6,82,745	5,65,111	6,35,072	7,16,075	8,03,230
<b>Interest earning assets</b>	<b>37,82,968</b>	<b>42,95,510</b>	<b>50,90,879</b>	<b>61,36,051</b>	<b>74,60,093</b>
Fixed assets	18,487	19,926	23,284	26,078	29,208
Other assets	2,18,291	2,62,604	3,15,096	3,78,279	4,57,719
<b>Total assets</b>	<b>40,19,746</b>	<b>45,78,041</b>	<b>54,29,259</b>	<b>65,40,409</b>	<b>79,47,020</b>
BVPS (Rs)	599.3	662.3	733.9	845.2	988.0
Adj. BVPS (INR)	584.8	646.6	716.9	826.7	965.8
Gross advances	24,30,389	29,40,350	35,28,414	43,39,949	53,38,137
Credit to deposit (%)	81.4	86.2	87.1	87.1	87.5
CASA ratio (%)	42.8	40.0	38.1	38.1	38.4
Cost of deposits (%)	4.5	5.0	6.0	5.9	5.6
Loans-to-Assets (%)	59.5	63.3	64.2	65.6	66.4
Net advances growth (%)	12.4	21.3	20.1	23.2	23.0
Deposit growth (%)	14.6	14.6	18.9	23.1	22.5
Book value growth (%)	8.4	10.5	10.8	15.2	16.9

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	23.9	14.9	11.9	9.9	7.9
P/B (x)	2.4	2.2	2.0	1.7	1.5
P/ABV (x)	2.4	2.2	2.0	1.7	1.5
P/PPOP (x)	8.6	7.7	6.8	5.6	4.5
Dividend yield (%)	0.6	1.0	1.3	1.6	1.8
<b>DuPont-RoE split (%)</b>					
NII/avg assets	3.9	4.1	4.1	4.1	4.2
Other income	1.9	1.9	1.9	1.9	1.9
Fee income	1.2	1.3	1.3	1.3	1.4
Opex	2.5	2.7	2.8	2.7	2.6
<b>PPOP</b>	<b>3.4</b>	<b>3.3</b>	<b>3.2</b>	<b>3.3</b>	<b>3.4</b>
Core PPOP	3.2	3.3	3.2	3.2	3.3
Provisions	1.7	1.0	0.8	0.8	0.8
Tax expense	0.4	0.6	0.6	0.6	0.7
<b>RoA (%)</b>	<b>1.2</b>	<b>1.7</b>	<b>1.9</b>	<b>1.9</b>	<b>1.9</b>
Leverage ratio (x)	8.5	8.5	8.6	8.9	9.3
<b>RoE (%)</b>	<b>10.2</b>	<b>14.5</b>	<b>15.9</b>	<b>16.7</b>	<b>18.1</b>

Quarterly data					
Rs mn, Y/E Mar	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24
NII	43,021	44,954	46,695	48,671	50,767
NIM (%)	4.2	4.3	4.3	4.3	4.3
PPOP	35,444	36,864	37,575	38,315	39,087
PAT	18,052	19,635	20,434	21,244	22,012
EPS (Rs)	23.29	25.34	26.34	27.38	28.37


Source: Company, Emkay Research

## RECOMMENDATION HISTORY - DETAILS

Date	CMP (INR)	TP (INR)	Rating	Analyst
18-Jul-23	1,390	1,800	Buy	Anand Dama
25-Apr-23	1,122	1,600	Buy	Anand Dama
09-Mar-23	1,170	1,650	Buy	Anand Dama
18-Jan-23	1,223	1,650	Buy	Anand Dama
20-Oct-22	1,160	1,500	Buy	Anand Dama
04-Oct-22	1,219	1,275	Buy	Anand Dama
28-Jul-22	1,018	1,275	Buy	Anand Dama
21-Jul-22	948	1,275	Buy	Anand Dama
01-May-22	979	1,350	Buy	Anand Dama
30-Jan-22	904	1,350	Buy	Anand Dama
07-Nov-21	1,189	1,460	Buy	Anand Dama
28-Oct-21	1,176	1,460	Buy	Anand Dama
05-Oct-21	1,169	1,375	Buy	Anand Dama
28-Jul-21	993	1,375	Buy	Anand Dama
22-Jun-21	1,000	1,375	Buy	Anand Dama
02-May-21	935	1,125	Buy	Anand Dama
30-Jan-21	846	1,175	Buy	Anand Dama
20-Jan-21	948	1,175	Buy	Anand Dama
31-Oct-20	586	660	Hold	Anand Dama

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of October 19, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of October 19, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 19, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	Over 15%
<b>HOLD</b>	Between -5% to 15%
<b>SELL</b>	Below -5%

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com



**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.